| Population 2015 |
182 million |
| |
| | | | | |
| Estimates of TB burden*, 2015 |
Number (thousands) |
Rate
(per 100 000 population) |
| Mortality (excludes HIV+TB) |
180 |
(96–290) |
99 |
(53–160) |
| Mortality (HIV+TB only) |
57 |
(43–74) |
31 |
(24–40) |
| Incidence (includes HIV+TB) |
586 |
(345–890) |
322 |
(189–488) |
| Incidence (HIV+TB only) |
100 |
(56–155) |
55 |
(31–85) |
| Incidence (MDR/RR-TB)** |
29 |
(15–43) |
16 |
(8.2–24) |
| |
| | | | | |
| Estimated TB incidence by age and sex (thousands)*, 2015 |
| |
0-14 years |
> 14 years |
Total |
| Females |
33 |
(14–52) |
198 |
(67–328) |
231 |
(82–380) |
| Males |
34 |
(20–47) |
322 |
(210–434) |
355 |
(229–481) |
| Total |
67 |
(43–91) |
519 |
(371–668) |
586 |
(345–890) |
| |
| | | | | |
| TB case notifications, 2015 |
|
| Total cases notified |
90 584 |
| Total new and relapse |
87 211 |
| - % tested with rapid diagnostics at time of diagnosis |
58% |
| - % with known HIV status |
100% |
| - % pulmonary |
94% |
| - % bacteriologically confirmed among pulmonary |
68% |
| |
| | | | | |
| Universal health coverage and social protection |
|
| TB treatment coverage (notified/estimated incidence), 2015 |
15% (9.8–25) |
| TB patients facing catastrophic total costs |
|
| TB case fatality ratio (estimated mortality/estimated incidence), 2015 |
0.43 (0.22–0.77) |
| |
| | | | | |
| TB/HIV care in new and relapse TB patients, 2015 |
Number |
(%) |
| Patients with known HIV-status who are HIV-positive |
14 846 |
17% |
| - on antiretroviral therapy |
11 141 |
75% |
| |
| | | | | |
| Drug-resistant TB care, 2015 |
New cases |
Previously treated
cases |
Total
number*** |
Estimated MDR/RR-TB cases among notified
pulmonary TB cases |
|
4 700
(3 700–5 700) |
| Estimated % of TB cases with MDR/RR-TB |
4.3% (3.2–5.4) |
25% (19–31) |
|
| % notified tested for rifampicin resistance |
40% |
64% |
50 274 |
| MDR/RR-TB cases tested for resistance to second-line drugs |
|
|
| Laboratory-confirmed cases |
MDR/RR-TB: 1 241, XDR-TB: 1 |
| Patients started on treatment **** |
MDR/RR-TB: 656, XDR-TB: 1 |
| |
| | | | | |
| Treatment success rate and cohort size |
Success |
Cohort |
| New and relapse cases registered in 2014 |
87% |
86 464 |
| Previously treated cases, excluding relapse, registered in 2014 |
83% |
4 890 |
| HIV-positive TB cases, all types, registered in 2014 |
79% |
17 014 |
| MDR/RR-TB cases started on second-line treatment in 2013 |
77% |
339 |
| XDR-TB cases started on second-line treatment in 2013 |
0% |
2 |
| |
| | | | | |
| TB preventive treatment, 2015 |
|
| % of HIV-positive people (newly enrolled in care) on preventive treatment |
20% |
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment |
16% (15–18) |
| |
| | | | | |
| TB financing, 2016 |
|
| National TB budget (US$ millions) |
257 |
| Funding source: 12% domestic, 33% international, 55% unfunded |
| |
| | | | | |
| * Ranges represent uncertainty intervals | | | | | |
| ** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin | | | |
| *** Includes cases with unknown previous TB treatment history | | | | |
| **** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed | | |
| | | | | |